Online inquiry

IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2780MR)

This product GTTS-WQ2780MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL1RL1 gene. The antibody can be applied in Allergic asthma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001282408.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 9173
UniProt ID Q01638
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2780MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14988MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ5352MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ10824MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA M7824
GTTS-WQ1608MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACE-536
GTTS-WQ15096MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ST2146
GTTS-WQ11653MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ15233MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA TAK-079
GTTS-WQ7389MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GA101
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW